Appeals body of European Patent Office upholds Myriad patent

A decision by the European Patent Office’s (EPO) Opposition Division to revoke a patent for diagnosing susceptibility to breast and ovarian cancer has been overturned by the EPO’s Technical Board of Appeal. However, the scope of the restored patent held by Myriad Genetics Inc has been reduced.

Location